Sirnaomics Ltd. (“Sirnaomics”; Stock Code: 02257.HK) completed its IPO and listing on the Main Board of the Hong Kong Stock Exchange (HKEX) on December 30, 2021 as China's first RNA therapeutics company to be listed on HKEX. The company offered 7,540,000 shares at HK$65.90 per share, raising approximately HK$490 million (before exercising the over-allotment option).

Founded in 2007, headquartered in Maryland, Sirnaomics is the first clinical-stage RNA therapeutics company to have a strong presence in both China and the U.S., as well as the first company to achieve positive Phase IIa clinical outcomes in oncology for an RNAi therapeutics for our core product, STP705. The company's product pipeline has over a dozen product candidates for a range of therapeutic indications across rare and large market diseases, covering fields such as cancer, fibrosis, cosmetology, viral diseases, cardiovascular diseases and cardiometabolic diseases. The company's key operators in China are Sirnaomics Biopharmaceuticals (Suzhou) Co., Ltd. and Sirnaomics Biopharmaceuticals (Guangzhou) Co., Ltd.

As the Chinese legal adviser to the sponsor and the underwriter, Jingtian & Gongcheng's legal team provided comprehensive and full-process legal services for the IPO and listing of Sirnaomics, thus successfully finishing the IPO-related legal work.